Equities

ANGN

US03476J1079

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
6.68 ^USD	+0.91%		-18.24%	-33.20%

2023	Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	CI
2023	Angion Biomedia to Implement 10-for-1 Reverse Split	MT

Angion Biomedica Corp. Reports Earnings Results for the Nine Months Ended September 30, 2020

January 15, 2021 at 05:18 pm

Angion Biomedica Corp. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced total revenue was USD 2.421 million compared to USD 791,000 a year ago. Operating loss was USD 41.423 million compared to USD 24.398 million a year ago. Net loss was USD 51.232 million compared to USD 24.643 million a year ago. Basic loss per share from continuing operations was USD 5.46 compared to USD 2.65 a year ago.

Latest news about ANGN BIOM

Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	23-08-30	CI
Angion Biomedia to Implement 10-for-1 Reverse Split	23-06-01	MT
Angion Biomedica Corp.(NasdaqGS:ANGN) dropped from NASDAQ Composite Index	23-06-01	CI
Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.	23-05-31	CI
Angion Biomedica Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Sector Update: Health Care Stocks Finishing Near Intra-Day Lows	23-01-17	MT
Sector Update: Health Care Stocks Sputtering in Tuesday Trading	23-01-17	MT
Top Midday Decliners	23-01-17	MT
Investors Digest More Big Bank Earnings, Weighing on US Equity Futures	23-01-17	MT
Top Premarket Decliners	23-01-17	MT
Angion Biomedica Agrees to Merge With Elicio Therapeutics	23-01-17	MT
Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others for $49 million in a reverse merger transaction.	23-01-16	CI
Angion Biomedica Gets Non-Compliance Notice From Nasdaq	22-12-22	MT
Angion Biomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Angion Biomedica Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Revenue $653,000	22-08-15	MT
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Loss $-0.30	22-08-15	MT
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value	22-07-25	CI
Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022	22-07-25	CI
Angion Biomedica to Explore Strategic Alternatives to Boost Shareholder Value	22-07-25	MT
HC Wainwright Downgrades Angion Biomedica to Neutral From Buy	22-07-18	MT
Sector Update: Health Care Stocks Swoon Late, Closing Lower	22-06-30	MT
Top Midday Decliners	22-06-30	MT
Sector Update: Health Care Stocks Little Changed on Thursday	22-06-30	MT
Sector Update: Health Care	22-06-30	MT

Chart ANGN BIOM

Duration

Period

More charts

Company Profile

Angion Biomedica Corp. is a clinical-stage company. The Company is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company's product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.

Sector

More about the company

Income Statement Evolution

More financial data